Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review.
Valerio Ricci, Domenico de Berardis, Giuseppe Maina
Healthcare (Basel, Switzerland) January 29, 2024 DOI: 10.3390/healthcare12030339 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative review Peer reviewed |
|---|---|
| Interventions | aripiprazole cariprazine brexpiprazole lurasidone |
| Keywords | Brexpiprazole Cariprazine Lurasidone Psychostimulants Schizophrenia Substance-induced psychosis Neuroleptics Antipsychotic medications antipsychotics Third-generation antipsychotics aripiprazole Psychotropics Toxic psychosis |
| Citations | 16 |
| Key findings | Third-generation antipsychotics may be effective for treating substance-induced psychosis, but more long-term research and integrated pharmacological-psychological approaches are needed. |
Abstract
This narrative review explores the efficacy and tolerability of third-generation antipsychotics (TGAs)-aripiprazole, cariprazine, brexpiprazole, and lurasidone-for the management of substance-induced psychosis (SIP). SIP is a psychiatric condition triggered by substance misuse or withdrawal, characterized by unique features distinct from those of primary psychotic disorders. These distinctive features include a heightened prevalence of positive symptoms, such as hallucinations and delusions, in addition to a spectrum of mood and cognitive disturbances. This review comprehensively investigates various substances, such as cannabinoids, cocaine, amphetamines, and LSD, which exhibit a greater propensity for inducing psychosis. TGAs exhibit substantial promise in addressing both psychotic symptoms and issues related to substance misuse. This review elucidates the distinctive pharmacological properties of each TGA, their intricate interactions with neurotransmitters, and their potential utility in the treatment of SIP. We advocate for further research to delineate the long-term effects of TGAs in this context and underscore the necessity for adopting an integrated approach that combines pharmacological and psychological interventions. Our findings underscore the intricate and multifaceted nature of treating SIP, highlighting the potential role of TGAs within therapeutic strategies.